Editorial

                     


February 1, 2012

RepliCel’s Update Shows Clinical Trial is on Track
Filed under: Spotlight Companies — Spotlight Companies @ 6:13 am

RepliCel Life Sciences Inc. REPCFRepliCel Life Sciences, Inc. (REPCF) recently provided an update on its first-in-man clinical trial, TS001-2009, for a potentially revolutionary new treatment for hair loss in men and women. The highly anticipated results from the initial six-month post injection follow-up period are nearly collected.

Seventeen of the 19 subjects have had their six-month follow-up visit. During these visits, they had their overall health evaluated, including subjective and objective assessments of the verum and placebo injection sites. Digital pictures were also taken of the scalp injection sites. The remaining two patients will complete their six-month follow-ups by the end of March, while four patients should finish their 12-month follow-ups by that same time.

The TS001-2009 study team will be doing thorough reviews of the data available throughout the months of March and April this year. When completed, this will lead to the study being “un-blinded,” so that the analysis team can analyze the collected data. The patients will also continue to be monitored through 2013 for any changes in their overall health.

New Treatment With Great Potential

At the core of RepliCel’s revolutionary new technology is an innovative process that focuses on the regenerative properties of the dermal sheath cup cells which are found in hair follicles. By extracting the cells from a patient’s healthy hair follicles–typically found in the lower area of the back of the scalp–and replicating them in a proprietary culture medium for several months, the company’s scientific team believes that by re-injecting these replicated cells back into balding areas on the patient’s scalp, they could potentially stimulate hair growth.

What results is a treatment that is minimally invasive and cosmetically preferable given that previous studies showed that the rejuvenated hair follicles grew in an evenly-distributed manor on SCID mice.

RepliCel Could Change Hair Loss Forever

The exciting potential of RepliCel’s new treatment lies in the way it uses a patient’s own hair follicles to create new hair growth. Not only does this mean getting back one’s real, natural hair, but it also has applications that previous treatments lacked. In particular, the treatment has the potential to offer females who had, to this point, lacked a strong treatment option for hair loss. 

Comments

comments


About Spotlight Companies

Spotlight Companies profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities (read more about Spotlight)...
|

Comments

No Comments »

RSS feed for comments on this post. TrackBack URL

Leave a comment

 

Sector News



Market Overview

Symbol Last Change % Change
DJIA15,387.5852.300.34
NASDAQ3,502.125.691530.16
S&P 500 EOD1,669.182.890.17
10yr Trsy19.44-0.26-1.32
Data is delayed 20 mins/EOD

Uncommon Wisdom with Fisher Investments

Fisher Investments
Japanese policymakers largely understand what their Chinese counterparts don’t—encouraging private firms to invest more and as they see fit is the best way to goad sustainable economic growth.

Behind the Frontlines with Mauldin Economics

John Mauldin
They aren't currency wars, they're currency tensions. -- Mohamed El-Erian. Either way, Japan is ruffling a lot of feathers as it exports deflation.

Richard Suttmeier of ValuEngine

Richard Suttmeier
The daily chart for MCP shows declining momentum with the stock above its 21-day and 50-day simple moving averages and below its 200-day simple moving average.